The global Transient Ischemic Attack Market is expected to grow at a CAGR of ~ 6.8 % during the forecast period 2017-2023.
Transient ischemic attack (TIA) are often called as mini-strokes. A transient ischemic attack is considered to be a major warning sign of an impending future stroke. Up to 10% of people will experience a stroke within three months of TIA.
Over the last decade, the number of hospitals has increased to a great extent, which has influenced the growth of the market positively. Moreover, increasing demand for better treatment and changing reimbursement policies have fueled the market growth.
Increasing prevalence of neurological disorder like transient ischemic attack, epilepsy, rising need for better treatment, increasing investment of biotechnology and pharmaceutical industries in R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapid development in technology will fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the review period.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/5025
The Americas dominates the global transient ischemic attack market owing to the presence of huge patient population with neurological disorder such as transient ischemic attack, epilepsy, and migraine, high healthcare spending, and increasing government support for research & development.
Europe holds the second largest share of the global transient ischemic attack market. The increasing focus of various government agencies on treating transient ischemic attack, epilepsy, depression, and heart attacks will have a positive impact on the growth of the market. The growing public awareness will boost the adoption of these devices in the Europe market.
Asia Pacific is the fastest growing transient ischemic attack market across the globe. Japan holds the major share of the regional market due to availability of technology and huge healthcare spending. Rapidly developing economy, increasing healthcare expenditure, and government initiatives for research & development will drive the market in China and India over the assessment period.
The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.
Access Report Details @ https://www.marketresearchfuture.com/reports/transient-ischemic-attack-market-5025
The global transient ischemic attack market has been segmented on the basis of diagnosis, treatment, and end user. On the basis of diagnosis, the market is segmented into imaging technique and others. Imaging technique is further segmented into magnetic resonance angiography (MRA), CT angiography (CTA), carotid ultrasonography/transcranial doppler ultrasonography, and others. On the basis of treatment, the market is segmented into surgery, antiplatelet medications, anticoagulant medications, and others. Surgery is further segmented into carotid endarterectomy and others. Antiplatelet medications is further segmented into clopidogrel, aspirin, and others. Anticoagulant medications is further segmented into warfarin, apixaban, and others. On the basis of end user, the market is segmented into hospitals & clinics, research Laboratories, and others.
Some of key the players in the market are LivaNova PLC (U.K), EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), Boston Scientific Corporation (US), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), ImThera Medical (U.S.), and Inspire Medical Systems, Inc.(U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others.